|
Updated: January 4, 2017
MA09-hRPE cell implantation is a regenerative approach to treating retinal disease being developed by Astellas and Ocata. The primary cause of Stargardt disease is the buildup of toxic vitamin A aggregates due to a genetic defect resulting in damage to retinal tissue. MA09-hRPE aims to correct this via injection of human stem cell derived RPE cells, with the goal of regenerating the damaged tissue.
|
Archives
May 2020
Topics
All
|